<DOC>
	<DOCNO>NCT00937820</DOCNO>
	<brief_summary>The study objective evaluate efficacy safety oral YM150 52 week patient history venous thromboembolism .</brief_summary>
	<brief_title>Prevention Recurrence Venous Thromboembolism Patients With History Venous Thromboembolism</brief_title>
	<detailed_description />
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Darexaban</mesh_term>
	<criteria>Subject symptomatic VTE and/or asymptomatic deep vein thrombosis Written inform consent obtain screen Subject history deep vein thrombosis and/or pulmonary embolism Subject hemorrhagic disorder and/or coagulation disorder Subject clinically important bleeding occur within 90 day prior screen visit Subject acute bacterial endocarditis Subject uncontrolled severe moderate hypertension , retinopathy , myocardial infarction stroke Subject receive anticoagulants/antiplatelet agent Subject body weight less 40 kg</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>YM150</keyword>
	<keyword>Bleeding</keyword>
	<keyword>VTE</keyword>
	<keyword>FXa inhibitor</keyword>
	<keyword>Venous thromboembolism</keyword>
</DOC>